Luo Xiaofang, Teng Qiu-Xu, Dong Jin-Yun, Yang Dong-Hua, Wang Meifeng, Dessie Wubliker, Qin Jiang-Jiang, Lei Zi-Ning, Wang Jing-Quan, Qin Zuodong, Chen Zhe-Sheng
Research Center of Biochemical Engineering Technology, College of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou, China.
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States.
Front Pharmacol. 2020 Aug 7;11:1208. doi: 10.3389/fphar.2020.01208. eCollection 2020.
Multidrug resistance (MDR) of tumor cells to chemotherapeutic agents is the main reason for the failure of cancer chemotherapy. Overexpression of ABCB1 transporter that actively pumps various drugs out of the cells has been considered a major contributing factor for MDR. Over the past decade, many antimicrobial peptides with antitumor activity have been identified or synthesized, and some antitumor peptides have entered the clinical practice. In this study, we report that peptide HX-12C has the effect of reversing ABCB1-mediated chemotherapy resistance. In ABCB1-overexpressing cells, nontoxic dose of peptide HX-12C inhibited drug resistance and increased the effective intracellular concentration of paclitaxel and other ABCB1 substrate drugs. The mechanism study showed that peptide HX-12C stimulated ABCB1 ATPase activity without changing the expression level and localization patterns of ABCB1. Molecular docking predicted the binding modes between peptide HX-12C and ABCB1. Overall, we found that peptide HX-12C reverses ABCB1-mediated MDR through interacting with ABCB1 and blocking its function without affecting the transporter's expression and cellular localization. Our findings suggest that this antimicrobial peptide may be used as a novel prospective cancer therapeutic strategy in combination with conventional anticancer agents.
肿瘤细胞对化疗药物的多药耐药性(MDR)是癌症化疗失败的主要原因。ABCB1转运蛋白过度表达,能将各种药物主动泵出细胞,被认为是导致多药耐药性的主要因素。在过去十年中,许多具有抗肿瘤活性的抗菌肽已被鉴定或合成,一些抗肿瘤肽已进入临床应用。在本研究中,我们报告肽HX-12C具有逆转ABCB1介导的化疗耐药性的作用。在ABCB1过表达的细胞中,无毒剂量的肽HX-12C抑制耐药性,并增加紫杉醇和其他ABCB1底物药物在细胞内的有效浓度。机制研究表明,肽HX-12C刺激ABCB1 ATP酶活性,而不改变ABCB1的表达水平和定位模式。分子对接预测了肽HX-12C与ABCB1之间的结合模式。总体而言,我们发现肽HX-12C通过与ABCB1相互作用并阻断其功能来逆转ABCB1介导的多药耐药性,而不影响转运蛋白的表达和细胞定位。我们的研究结果表明,这种抗菌肽可作为一种新的前瞻性癌症治疗策略,与传统抗癌药物联合使用。